- Funding Will Accelerate Miist’s Two Active Programs in Migraine and Smoking Cessation
- Phase 1 Smoking Cessation Trial Demonstrates Unmatched Speed with 92% Symptom Relief in Only 2 Minutes
- Scalable Approach and Technology Opens Up Instant Relief for Many Therapeutic Areas
Miist Therapeutics, a physics-based developer of inhaled medicines, today announced $7M in seed funding from investors including Refactor Capital, 1517 Fund, Freeflow Ventures, Entrepreneur First, and California Innovation Fund, among others. Miist has clinically validated its approach and is currently advancing two assets: MST-01 for the treatment of smoking addiction and MST-02 for the treatment of migraine. Phase 1 results for MST-01 demonstrate the speed of Miist’s therapies, with patients achieving 92% symptom relief in only 2 minutes post dosing.
Drawing on the experience of Miist’s CTO Jeff Schuster, a Berkeley Physics PhD and aerosol drug delivery veteran, the company has developed a proprietary inhaler that generates sterile aqueous drug particles small enough to reach the peripheral lung. These aerosol drug particles are created using vibration, not heat, and are solely composed of water (the carrier) and the selected pharmaceutical molecule. When these particles reach the peripheral lung, where the blood-air barrier is 100x thinner than a single human hair, they are instantly absorbed across this barrier and into the bloodstream. Miist has clinically validated that this approach achieves peak plasma drug levels in less than 30 seconds, approximately 100x faster than the absorption of a pill.
“So many therapeutic areas today are dominated by oral treatments that work far slower than patients want. A great example is migraine: when someone is suffering through debilitating migraine symptoms, they don’t want to wait an hour for their pill to kick in. Their #1 priority is getting fast relief and that’s what we’re uniquely positioned to deliver,” said Miist Therapeutics’ CEO and co-founder, Dalton Signor.
Zal Bilimoria, GP of Refactor Capital, is one of the earliest and largest backers behind Miist’s mission. “The Miist team has executed across every phase of development, from early technical R&D through human clinical studies. With these Phase 1 trial results validating the rapid action of their peripheral lung delivery and multiple active programs already in development, there is a real opportunity here to set a new treatment standard for many conditions,” says Bilimoria.
Miist Therapeutics’ founding team brings a diverse set of experiences and viewpoints that have been key to the company’s success. Before joining forces and setting up their Bay Area HQ, Dalton Signor (CEO) was recruited by Entrepreneur First and started building Miist full time in London, Eric Ezerins (Head of R&D) had begun a career in ocular biotherapeutic drug delivery, and Jeff Schuster (CTO) had already established himself as one of the top technical minds in inhalation drug delivery.
With this funding, the company is now positioned to accelerate its assets one step closer to the nearly 100 million patients who need them globally.
Discover the latest trends and insights—explore the Business Insights Journal for up-to-date strategies and industry breakthroughs!
